Splenic involvement by blastic mantle cell lymphoma (large cell/anaplastic variant) mimicking splenic marginal zone lymphoma

American Journal of Hematology

Volumn 62, Issue 4, 1999, Pages 242-246

  Mollejo, M ^a   Lloret, E ^a   Solares, J ^b   Bergua, J M ^b   Mateo, M ^a   Piris, M A ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b Dept Pathol of S Pedro Alcantara ^*  (Spain)

Author keywords

Mantle cell lymphoma; Marginal zone; Spleen

Indexed keywords

ADULT; ARTICLE; CANCER INVASION; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; SPLEEN DISEASE; SPLENECTOMY;

AGED; ANTIGENS, CD; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER; LYMPH NODES; LYMPHOMA; LYMPHOMA, MANTLE-CELL; MALE; SPLEEN; SPLENIC NEOPLASMS;

EID: 0032728692     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199912)62:4<242::AID-AJH8>3.0.CO;2-A     Document Type: Article

References (16)

1. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991;78:206-209.
2. Troussard X. Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, Henry-Amar M, Bryon PA. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996;93:731-736.
3. Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994;84:3828-34.
4. Isaacson PG, Piris MA. Splenic marginal zone lymphoma. Adv Anatomic Pathol 1997;4:191-201.
5. Mollejo M, Menárguez J, Lloret E, et al. Splenic marginal zone lymphoma. A distinctive type of low grade B-cell lymphoma. Am J Surg Pathol 1995;19:1146-1157.
6. Pittaluga S, Verhoef G, Criel A, Wlodarska I, Dierlmamm J, Mecucci C, Van den Berghe H, De Wolf Peelers C. "Small" B-cell Non-Hodgkin's Lymphomas with splenomegaly at presentation are either mantle cell lymphoma or marginal zone cell lymphoma. A study based on histology, cytology, immunohistochemistry, and cytogenetic analysis. Am J Surg Pathol 1996;20:211-223.
7. Schmid C, Kirkham N, Diss T, Isaacson PG: Splenic marginal zone lymphoma. Am J Surg Pathol 1992;16:455-466.
8. Alkan S, Ross CW, Curtis A, Hanson A, Schnitzer B. Follicular lymphoma with involvement of the splenic marginal zone: a pitfall in the differential diagnosis of splenic marginal zone cell lymphoma. Hum Pathol 1996;27:503-506.
9. Schmid U, Cogliatti SB, Diss TC, Isaacson PG. Monocytoid/marginal zone B-cell differentiation in follicle centre cell lymphoma. Histopathology 1996;29:201-208.
10. Swerdlow SH, Zukerber LR, Yang WI, Harris NL, Williams ME. The morphologic spectrum of non-Hodgkin's Lymphomas with Bcll/ CyclinD1 gene rearrangements. Am J Surg Pathol 1996;20:627-640.
11. Greiner TC, Moynihan MJ, Chan WC, Lytle D, Pedersen A, Anderson JR, Weisenburger DD. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996;87:4302-4310.
12. Hernández L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffeld M. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996;87:3351-3359.
13. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VVVS, Schluger A, Chaganti RSK. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 1995;86:2892-2899.
14. Pinyol M, Hernández L, Cazorla M, Balbin M, Jares P, Fernandez PL, Montserrat E, Cardesa A, López-Otín, Campo E. Deletions and loss of expression of p16 and p21 genes are associated with aggressive variants of mantle cell lymphoma. Blood 1997;89:272-280.
15. Zoldan MC, Inghirami G, Masuda Y, Vandekerckhove, Raphael B, Amorosi E, Hymes K, Frizzera G. Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 1996;93:475-486.
16. Villuendas R, Pezella F, Gatter K, Algara P, Sánchez-Beato M, Martínez P, Martínez JC, Muñoz K, García P, Sánchez L, Kocialkowsky S, Campo E, Orradre JL, Piris MA. P21 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-,p21-immunophenotype associated with missense p53 mutations. J Pathol 1997;181:51-61.